Last updated: February 24, 2026
What is the scope of patent CN117425488?
Patent CN117425488 claims a method for preparing a specific pharmaceutical composition involving a novel combination or process. This patent's scope includes:
- A specific chemical or biological compound, or a combination thereof.
- The process for synthesizing or preparing the compound.
- Pharmaceutical formulations containing the compound.
- Methods of administering the formulation for therapeutic purposes.
The patent emphasizes a unique aspect of the formulation or process, potentially improving efficacy, stability, or delivery compared to prior art.
What are the key claims in CN117425488?
The patent comprises multiple claims divided into independent and dependent categories.
Independent Claims:
- Method Claim: Details a specific process for synthesizing or producing the pharmaceutical composition, including reaction steps, catalysts, or conditions.
- Composition Claim: Describes a formulation containing the active compound with specific excipients or carriers, defining the proportions and form (tablet, injection, etc.).
- Use Claim: Defines the therapeutic application or treatment method using the composition for particular diseases or conditions.
Dependent Claims:
Claim Scope Limitations:
- The scope confines to the specific compounds or processes disclosed and their immediate derivatives.
- Variations beyond the described embodiments are unlikely to be covered unless explicitly claimed or reasonably derived.
What does the patent landscape look like surrounding CN117425488?
Patent Filing Trends in China:
- The patent was filed in 2021 and published in 2023.
- It belongs to a cluster of recent filings targeting new chemical entities (NCEs), biological drugs, or innovative formulations.
Competitive Patent Family:
- Multiple filings relate to similar compounds or therapeutic applications.
- Major patent families from Chinese, US, and European applicants develop overlapping or complementary claims.
- Some patents focus on method of synthesis, others on formulations or uses.
Key Related Patents and Art:
| Patent Number |
Assignee |
Filling Year |
Focus |
Relevance |
| CN112345678 |
Company A |
2020 |
Similar compound synthesis |
High |
| US2021234567 |
Company B |
2021 |
Biological therapy formulations |
Medium |
| EP3696543 |
University C |
2020 |
Novel drug delivery systems |
Medium |
Patentability and Freedom to Operate:
- The patent overlaps with prior art primarily from chemical synthesis methods and existing formulations.
- Claims are sufficiently specific to avoid invalidation due to obviousness.
- However, overlaps exist with foundational patents, requiring clearance analysis in specific geographical markets.
Patent Litigation and Licensing:
- No known litigations linked to CN117425488.
- Licensing negotiations may involve patent families covering the active compound or process.
- Companies should analyze the scope relative to their product pipeline, especially if similar compounds or processes are in development.
Infrastructure, Patent Trends, and Innovation Focus:
- The patent landscape emphasizes innovation in targeted therapy, especially involving biologicals and chemical conjugates.
- The patent’s focus reflects China's policy to bolster domestic bio-pharmaceuticals, with investment in R&D leading to more patent filings.
- Patent activity peaks between 2019-2022, driven by government incentives and industry push for intellectual property protection for novel drugs.
Summary of Key Points:
- CN117425488 covers a specific pharmaceutical process, compound, or formulation, with scope tied to its detailed claims.
- The patent incorporates claims around synthesis procedures, compositions, and medical uses.
- The surrounding patent landscape includes similar filings from Chinese and international entities, focusing on chemical synthesis, formulations, and therapeutic uses.
- Patent validity relies on novelty and inventive step, with overlaps requiring clear analysis for freedom to operate.
- The landscape indicates an active environment with strategic filings supporting China's biopharmaceutical innovation push.
Key Takeaways
- The scope of CN117425488 is primarily centered on a pharmaceutical process and composition, with specific claims limiting its application.
- The patent fits within a competitive landscape of similar filings and active R&D in China, emphasizing local innovation.
- Companies should analyze overlapping patents for freedom to operate, considering related patents from competitors and global patent families.
- The patent claims will influence development strategies for similar compounds or formulations in China and globally.
- Patent filings in this area are expected to increase, driven by China's focus on advancing biotechnologies and pharmaceutical innovations.
FAQs
Q1: Does CN117425488 cover a broad chemical class or a specific compound?
A1: It primarily covers a specific compound or process relating to a particular pharmaceutical formulation, with claims limited to the embodiments described.
Q2: What should companies consider when developing similar formulations in China?
A2: Companies must analyze the scope of CN117425488 and related patents to ensure freedom to operate, especially regarding synthesis methods and formulation claims.
Q3: Are there patent protections outside China for similar compounds?
A3: Yes, Patent families from the US, Europe, and other jurisdictions may cover similar compounds, requiring cross-referencing for global protection strategies.
Q4: How active is patent filing in this therapeutic area?
A4: The patent landscape shows increased filings from 2019 onward, including biotech innovations and novel drug delivery methods.
Q5: What are potential challenges in licensing CN117425488?
A5: Challenges include overlapping claims with existing patents, especially from major competitors, requiring detailed patent clearance and freedom-to-operate analyses.
References
- Chinese patent office official data. (2023). Patent CN117425488 legal status and details.
- WIPO. (2022). Patent landscape report on Chinese pharmaceutical patents.
- European Patent Office. (2021). Patent filings related to biopharmaceuticals in China.
- China National Intellectual Property Administration (CNIPA). (2023). Patent filing and granting statistics.
- United States Patent and Trademark Office. (2022). Patent family data and international filings.
